Corporate Deck January

January 2026

1

Diverse Program

Pipeline

Broad pipeline across neuro, salivary gland, and ophthalmology

End-to-End GMP

Manufacturing

In-house manufacturing and industry-leading process

Next-Generation

Vector Optimization

Improved potency C safety, lower dose and lower COGS

Transformative in vivo

production Technology

Proprietary Riboswitch platform for precise control of therapeutic proteins

1 Remaining interests in program sold to Johnson s Johnson Innovative Medicine in December 2023; MeiraGTx to receive up to an aggregate of $350.0 million upon achievement of milestones and will manufacture and supply commercial product for Johnson s Johnson Innovative Medicine

4

Broad Pipeline of Transformative Genetic Medicines

Advanced clinical programs across multiple therapeutic areas

1 Joint venture with Hologen AI (see press release here)

2 Remaining interests in program sold to Johnson s Johnson Innovative Medicine in December 2023; MeiraGTx to receive up to an aggregate of $350.0 million upon achievement of milestones and will manufacture and supply commercial 5

product for Johnson s Johnson Innovative Medicine

01 02 03 04

Radiation-Induced

Xerostomia

• Pivotal Phase 2

• Potential BLA filing early 2027

• Large patient population with no effective therapies available

• 'Pipeline in a product'

  Parkinson's

  Disease

• Phase 3 ready

• Potential BLA filing in 2028

• Large patient population inadequately controlled by dopamine therapy

  AIPL1-Associated Congenital Blindness

• Developed under 'specials'

  license

• Near term BLA and MAA filings-FDA and MHRA

• Potential approvals 2026

• Transformative effect - 11/11 blind to seeing children under 4 years

  X-Linked Retinitis Pigmentosa (RPGR)

• Completed Phase 3

• BLA and MAA ready -

  Clinical and PPQ

• Acquired by Johnson C Johnson Innovative Medicine; MeiraGTx manufactures commercial product

End-to-end internal manufacturing infrastructure, capabilities and production process

Best in class, fully end-to end internal capabilities: Two flexible C scalable cGMP vector production facilities, London, UK and Shannon, Ireland; cGMP plasmid production facility; cGMP QC facility for release and stability; fill and finish; dedicated MSAT process development facility

Commercial licenses in Ireland and UK for

viral vector production and QC

Proprietary Commercial Ready Manufacturing Process at IND: Saves 2-3 years in AAV clinical development timeline from IND to commercial and allows faster move to pivotal with expedited time to market

Global regulatory relationships and extensive

experience from pre-IND through BLA/commercial

Commercial grade manufacturing with scalable and flexible capacity, clinical and commercial supply

7

Potency C safety optimization and precise control of gene expression

In-house vector engineering platforms

Extensive in-house vectorology capabilities addressing each element of the vector genome sequence

Promoter engineering s discovery

>250k promoter library

Combine rational design, massive high throughput screening, and AI to optimize proprietary promoters

ITR

Gene sequence optimization Intron/exon configuration, poly A, translation efficiency, mRNA stability, reduced immunogenicity

ITR

Promoter/ enhancer

Intron Therapeutic gene

Poly A

Vector Engineering

Platforms

Capsid design

Proprietary capsids with high transduction efficiency, including novel intravitreal capsids targeting back or front of the eye - screened directly in NHPs; muscle and CNS capsids

Riboswitch gene regulation

Precise dose responsive control

of in vivo therapeutic protein production with bespoke oral small molecule inducer

Manufacturability

Optimal plasmid design and vector genome

sequence optimization for industry-leading high yield and full/empty ratio

8

Riboswitch technology enables unprecedented

precise in vivo delivery of biologic therapeutics with orally administered inducers

1

Riboswitch-regulated therapeutic transgene is delivered via AAV, other vector, or via gene editing

2 Oral pill induces

precise production of the peptide or protein therapeutic

+

Small molecule

Unbound Aptamer

Expression Platform

OFF

Bound Aptamer

Expression Platform

ON

Riboswitch technology can be applied

across many therapeutic areas and modalities, providing titratable control of gene expression with an oral pill

Vectorized biologics

Cell Therapy

Gene Editing

Short-lived hormones s peptides

Control CNS s PNS Therapies

Control Ocular Therapies

9

A broad range of therapeutic proteins encoded by Riboswitch-containing transgenes show tight control via oral small molecule dosing, in vivo

Therapeutic Antibodies

Cell Therapy

Therapeutic Hormones/Cytokines

/ Peptides

Gene/RNA Editing Nucleases

• Anti-PCSK9

• Anti-VEGFR2 (eye)

• Anti-Amyloid

• Anti-IL-17

• Anti-PD1

• Anti-HER2

• Anti-IL4Ra

• Anti-Myostatin

  RiboCAR:

• Anti-CD19

• Anti-PSMA

• Anti-mesothelin

• Anti-HER2

• Cytokines

• ProTcell (progenitor T cell)

  derived riboCAR-T

• Epo

• hGH

• PTH

• Insulin

• GLP-1R agonists

• Gut peptide combinations: GLP1- GIP; GLP1, GIP, PYY,

  Glucagon, Amylin,

  Oxyntomodulin

• Myokines

• Adipokines e.g: leptin

• Cas9

• CasRx

10